News
Amelia-1 Clinical Trial Fully Open To Recruitment, 1st Patient Data on Combination Study with PI3K Inhibitor and SERD
SynDevRx, Inc. today announced the opening of the Amelia-1 study and data from the first patient treated in its Phase 1b/2 clinical study testing the novel MetAP2 inhibitor evexomostat (aka SDX-7320) in combination with the PI3K inhibitor alpelisib (Piqray®) and the estrogen receptor degrader (SERD) drug fulvestrant (Faslodex®) in breast cancer patients with metastatic disease […]
New Experimental Treatment for Prostate Cancer Revealed at AACR
SDX AACR 2023 poster 05Apr 2023.pptx PRESS RELEASE • APR 14, 2023 08:00 EDT Evexomostat (SDX-7320) shows potent anti-tumor effects in pre-clinical models of prostate cancer, including castration-resistant. New research data to be presented at AACR 2023 in Orlando, FL
SynDevRx Joins ‘Touch – The Black Breast Cancer Alliance’ CEO Ricki Fairley in Metabo-Oncology Podcast – Wed. Oct 5, 2022 at 6:00 PM
Aug. 31, 2022 – SynDevRx Presents Scientific Poster on Anti-Fibrosis Data with Evexomostat at the 2022 IPF Conference in Boston
Aug. 31, 2022 – SynDevRx, Inc., a clinical-stage biotechnology company leading the development of treatments for obesity-accelerated cancers, today announced the presentation of new scientific data on its lead compound evexomostat (SDX-7320) in a series of fibrosis models demonstrating potent anti-fibrosis data monotherapy and in combination with the standard of care therapy nintedanib. Evexomostat significantly […]
Breast Cancer Conversations: What You Need To Know About Your Metabolic Health and Breast Cancer
What You Need To Know About Your Metabolic Health and Breast Cancer Breast Cancer Conversations is a podcast that discusses all things breast cancer! We share stories of those who have been diagnosed. We interview medical professionals, doctors, radiologists, and oncologists. We speak with advocates and caregivers. We are your voice! If you have questions, […]
New Phase 1b/2 Clinical Research Study with SynDevRx Drug Evexomostat (SDX-7320) Announced for Triple-Negative Breast Cancer Patients with Baseline Insulin Resistance
SynDevRx, Inc. today announced the opening of a first-of-its-kind Phase 1b/2 study for patients with triple-negative breast cancer and baseline insulin resistance, testing the novel drug evexomostat (SDX-7320) in combination with standard-of-care treatment Halaven (eribulin, Esai). Evexomostat is among the first anti-cancer therapeutics being developed specifically for cancer patients with baseline metabolic dysfunction (obesity, type […]
Prostate Cancer Research Collaboration with Australia Univ. of Technology, Prof. Colleen Nelson, PhD
QUT SDX Collaboration Press Release 07Dec 2021 – Part of an ongoing investigation focused on how obesity and dysregulated metabolic hormones promote prostate cancer progression and metastasis – Studies aim to quantify the ability of SynDevRx MetAP2 inhibitor evexomostat (SDX-7320) to control tumor growth of castration resistant prostate cancers
2021 San Antonio Breast Cancer Symposium Poster Presentation (SDX-7320+Capivasertib in Her2+ model)
SynDevRx Announces Research Collaboration with Maine Medical Center Research Institute to Study the Effects of SDX-7320 In Obesity-Accelerated Multiple Myeloma Models
SynDevRx, Inc., a clinical-stage biotechnology company leading the development of treatments for obesity-accelerated cancers, today announced a research collaboration with Maine Medical Center Research Institute’s Michaela Reagan, PhD. The collaboration will study the role of MetAP2 in obesity-accelerated growth and metastatic potential of multiple myeloma – a form of cancer that develops in bone marrow. […]
Obesity, Type 2 Diabetes,and Cancer Risk
Obesity and type 2 diabetes have both been associated with increased cancer risk and are becoming increasingly prevalent. Metabolic abnormalities such as insulin resistance and dyslipidemia are associated with both obesity and type 2 diabetes and have been implicated in the obesity-cancer relationship. Multiple mechanisms have been proposed to link obesity and diabetes with cancer […]